PortfoliosLab logoPortfoliosLab logo
ALNY vs. SNY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ALNY vs. SNY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi (SNY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ALNY achieves a -28.05% return, which is significantly lower than SNY's -6.78% return. Over the past 10 years, ALNY has outperformed SNY with an annualized return of 15.09%, while SNY has yielded a comparatively lower 4.63% annualized return.


ALNY

1D
-3.22%
1M
-3.37%
YTD
-28.05%
6M
-38.46%
1Y
-6.52%
3Y*
13.89%
5Y*
14.20%
10Y*
15.09%

SNY

1D
-0.37%
1M
-1.96%
YTD
-6.78%
6M
-9.38%
1Y
-8.16%
3Y*
-1.21%
5Y*
0.44%
10Y*
4.63%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ALNY vs. SNY - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ALNY
Alnylam Pharmaceuticals, Inc.
-28.05%68.99%22.94%-19.46%40.14%30.48%12.85%57.96%-42.61%239.34%
SNY
Sanofi
-6.78%4.93%1.09%6.55%0.57%7.00%0.39%20.47%6.06%9.96%

Correlation

The correlation between ALNY and SNY is 0.26, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.26

Correlation (3Y)
Calculated over the trailing 3-year period

0.19

Correlation (5Y)
Calculated over the trailing 5-year period

0.18

Correlation (10Y)
Calculated over the trailing 10-year period

0.23

Correlation (All Time)
Calculated using the full available price history since Jun 2, 2004

0.26

Fundamentals

Market Cap

ALNY:

$39.55B

SNY:

$103.08B

EPS

ALNY:

$4.26

SNY:

$3.09

PE Ratio

ALNY:

67.11

SNY:

13.86

PS Ratio

ALNY:

9.04

SNY:

2.21

PB Ratio

ALNY:

36.78

SNY:

1.42

Total Revenue (TTM)

ALNY:

$4.29B

SNY:

$47.35B

Gross Profit (TTM)

ALNY:

$2.51B

SNY:

$34.18B

EBITDA (TTM)

ALNY:

$729.86M

SNY:

$12.63B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ALNY vs. SNY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ALNY
ALNY Risk / Return Rank: 3232
Overall Rank
ALNY Sharpe Ratio Rank: 3333
Sharpe Ratio Rank
ALNY Sortino Ratio Rank: 2929
Sortino Ratio Rank
ALNY Omega Ratio Rank: 2929
Omega Ratio Rank
ALNY Calmar Ratio Rank: 3535
Calmar Ratio Rank
ALNY Martin Ratio Rank: 3535
Martin Ratio Rank

SNY
SNY Risk / Return Rank: 2323
Overall Rank
SNY Sharpe Ratio Rank: 2727
Sharpe Ratio Rank
SNY Sortino Ratio Rank: 2424
Sortino Ratio Rank
SNY Omega Ratio Rank: 2323
Omega Ratio Rank
SNY Calmar Ratio Rank: 2323
Calmar Ratio Rank
SNY Martin Ratio Rank: 1919
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ALNY vs. SNY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi (SNY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ALNYSNYDifference

Sharpe ratio

Return per unit of total volatility

-0.18

-0.33

+0.15

Sortino ratio

Return per unit of downside risk

-0.01

-0.28

+0.28

Omega ratio

Gain probability vs. loss probability

1.00

0.96

+0.04

Calmar ratio

Return relative to maximum drawdown

-0.14

-0.51

+0.36

Martin ratio

Return relative to average drawdown

-0.27

-1.01

+0.75

ALNY vs. SNY - Sharpe Ratio Comparison

The current ALNY Sharpe Ratio is -0.18, which is higher than the SNY Sharpe Ratio of -0.33. The chart below compares the historical Sharpe Ratios of ALNY and SNY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ALNYSNYDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.18

-0.33

+0.15

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.29

0.02

+0.27

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.28

0.20

+0.08

Sharpe Ratio (All Time)

Calculated using the full available price history

0.32

0.20

+0.12

Drawdowns

ALNY vs. SNY - Drawdown Comparison

The maximum ALNY drawdown since its inception was -83.58%, which is greater than SNY's maximum drawdown of -46.46%. Use the drawdown chart below to compare losses from any high point for ALNY and SNY.


Loading charts...

Drawdown Indicators


ALNYSNYDifference

Max Drawdown

Largest peak-to-trough decline

-83.58%

-46.46%

-37.12%

Max Drawdown (1Y)

Largest decline over 1 year

-42.01%

-16.70%

-25.31%

Max Drawdown (3Y)

Largest decline over 3 years

-42.01%

-23.37%

-18.64%

Max Drawdown (5Y)

Largest decline over 5 years

-42.46%

-33.52%

-8.94%

Max Drawdown (10Y)

Largest decline over 10 years

-59.95%

-33.52%

-26.43%

Current Drawdown

Current decline from peak

-41.75%

-20.60%

-21.15%

Average Drawdown

Average peak-to-trough decline

-30.59%

-12.19%

-18.40%

Ulcer Index

Depth and duration of drawdowns from previous peaks

22.69%

8.39%

+14.30%

Volatility

ALNY vs. SNY - Volatility Comparison

Alnylam Pharmaceuticals, Inc. (ALNY) has a higher volatility of 8.50% compared to Sanofi (SNY) at 5.39%. This indicates that ALNY's price experiences larger fluctuations and is considered to be riskier than SNY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ALNYSNYDifference

Volatility (1M)

Calculated over the trailing 1-month period

8.50%

5.39%

+3.11%

Volatility (6M)

Calculated over the trailing 6-month period

25.96%

14.94%

+11.02%

Volatility (1Y)

Calculated over the trailing 1-year period

36.45%

24.93%

+11.52%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

48.86%

24.68%

+24.18%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

53.69%

23.42%

+30.27%

Dividends

ALNY vs. SNY - Dividend Comparison

ALNY has not paid dividends to shareholders, while SNY's dividend yield for the trailing twelve months is around 5.66%.


PositionTTM20252024202320222021202020192018201720162015
ALNY
Alnylam Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
SNY
Sanofi
5.66%4.56%4.22%3.83%4.32%3.80%3.61%3.47%4.29%3.82%4.11%3.77%

Financials

ALNY vs. SNY - Financials Comparison

This section allows you to compare key financial metrics between Alnylam Pharmaceuticals, Inc. and Sanofi. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20222023202420252026
1.17B
11.24B
(ALNY) Total Revenue
(SNY) Total Revenue
Values in USD except per share items

ALNY vs. SNY - Profitability Comparison

The chart below illustrates the profitability comparison between Alnylam Pharmaceuticals, Inc. and Sanofi over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%202220232024202520260
72.1%
Portfolio components
ALNY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 1.17B. Therefore, the gross margin over that period was 0.0%.

SNY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Sanofi reported a gross profit of 8.11B and revenue of 11.24B. Therefore, the gross margin over that period was 72.1%.

ALNY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported an operating income of 268.64M and revenue of 1.17B, resulting in an operating margin of 23.0%.

SNY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Sanofi reported an operating income of 2.27B and revenue of 11.24B, resulting in an operating margin of 20.2%.

ALNY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported a net income of 205.99M and revenue of 1.17B, resulting in a net margin of 17.7%.

SNY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Sanofi reported a net income of 1.61B and revenue of 11.24B, resulting in a net margin of 14.4%.


Frequently Asked Questions


ALNY and SNY have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ALNY has higher volatility (8.50%) compared to SNY (5.39%). In terms of maximum drawdown, ALNY dropped -83.58% vs SNY's -46.46%.

ALNY currently has the higher Sharpe Ratio (-0.18 vs -0.33), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ALNY and SNY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer